Umeå University's logo

umu.sePublikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
The use of IL-17 and IL-23 inhibitors in Swedish clinical practice: a register-based analysis
The Swedish Institute of Health Economics (IHE), Lund, Sweden.
The Swedish Institute of Health Economics (IHE), Lund, Sweden.
Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Dermatologi och venereologi.ORCID-id: 0000-0002-3858-8474
2023 (engelsk)Inngår i: Dermatology, ISSN 1018-8665, E-ISSN 1421-9832, Vol. 239, nr 2, s. 262-266Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

BACKGROUND: Interleukin (IL) inhibitors have made completely cleared skin achievable for many patients with moderate to severe psoriasis in clinical trial settings. Few observational studies assess treatment response in accordance with treatment goals in guidelines.

OBJECTIVES: The aim of the study was to analyze the treatment response of IL-17/IL-23 inhibitors in clinical practice and the proportions of patients that reach the treatment target of the Psoriasis Area and Severity Index (PASI) < 3 and the Dermatology Life Quality Index (DLQI) ≤5.

METHODS: A longitudinal, observational study based on the Swedish National Registry for Systemic Treatment of Psoriasis, PsoReg. Patients using IL-17/IL-23 inhibitors with assessments of PASI, DLQI, and EQ-5D before (maximum 6 months) and after (3-12 months) initiation of IL-17/IL-23 were included.

RESULTS: In total, 333 patients using IL-17/IL-23 inhibitors were included. Eighty percent (n = 266) received IL-17 inhibitors, and 20% (n = 67) received IL-23 inhibitors. Sixty-six percent of patients reached both PASI <3 and DLQI ≤5, 23% reached one target, and 11% reached none. The mean (SD) PASI, DLQI, and EQ-5D improvements were 6.75 (6.99), 7.14 (7.97), and 0.126 (0.296), respectively. There was no statistically significant difference in outcomes between IL-17 and IL-23 inhibitor treatment groups.

CONCLUSIONS: IL-17/IL-23 inhibitors are effective in clinical practice, but there is still an unmet therapeutic need in moderate to severe psoriasis.

sted, utgiver, år, opplag, sider
S. Karger, 2023. Vol. 239, nr 2, s. 262-266
Emneord [en]
DLQI, EQ-5D, Interleukin inhibitors, PASI, Psoriasis
HSV kategori
Forskningsprogram
dermatologi och venereologi
Identifikatorer
URN: urn:nbn:se:umu:diva-201766DOI: 10.1159/000528007ISI: 000898408100001PubMedID: 36516805Scopus ID: 2-s2.0-85145581075OAI: oai:DiVA.org:umu-201766DiVA, id: diva2:1720009
Tilgjengelig fra: 2022-12-16 Laget: 2022-12-16 Sist oppdatert: 2023-07-14bibliografisk kontrollert

Open Access i DiVA

fulltext(160 kB)41 nedlastinger
Filinformasjon
Fil FULLTEXT02.pdfFilstørrelse 160 kBChecksum SHA-512
afd61f62b1309639152144e08bec8d7764fe3f5712f3b5dacab99b6f5e9042b08cb126ef60e1464f4bcee7d0939b45cbebd44bd3c8a26c951149fa6a8937cfd3
Type fulltextMimetype application/pdf

Andre lenker

Forlagets fulltekstPubMedScopus

Person

Schmitt-Egenolf, Marcus

Søk i DiVA

Av forfatter/redaktør
Schmitt-Egenolf, Marcus
Av organisasjonen
I samme tidsskrift
Dermatology

Søk utenfor DiVA

GoogleGoogle Scholar
Totalt: 104 nedlastinger
Antall nedlastinger er summen av alle nedlastinger av alle fulltekster. Det kan for eksempel være tidligere versjoner som er ikke lenger tilgjengelige

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 293 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf